Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV001225275 | SCV001397542 | likely pathogenic | Glanzmann thrombasthenia | 2023-10-17 | reviewed by expert panel | curation | The NM_000419.5(ITGA2B):c.2975del (p.Glu992GlyfsTer?) variant has been described in at least one patient with a phenotypes highly specific to GT including mucocutaneous bleeding, impaired aggregation with all agonists except ristocetin (PMID: 22190468; PP4_moderate). This patient is compound heterozygous with Gln778Pro (classified as Pathogenic by the ClinGen Platelet Disorders VCEP) in trans (PM3). This frameshift variant occurs in exon 28 and results in 51 altered amino acids followed by as stop loss and the elongation of the protein by 90 amino acids, which alters the entirety of the transmembrane domain which is critical to protein function (PMID: 25617834) as well as the cytoplasmic domain (PVS1_Strong). The variant is reported in 1/18394 alleles (frequency of 0.00005437) in the East Asian population in gnomAD, which meets the threshold <0.0001 alleles (PM2_supporting). In summary, this variant meets criteria to be classified as likely pathogenic for GT. GT-specific criteria applied: PM2_supporting, PVS1_strong, PM3, PP4_moderate. (PD-VCEP specifications v2.1) |